CDK1 and central nervous system cancer: In 2022, by viability and toxicity assays, clone formation assays, and tumor sphere invasion experiments, Christin Riess et al. (2022) explored the anti-glioma effects of abemaciclib, a selective CDK4/6 inhibitor, and dinaciclib, a more comprehensive CDK1/2/5/9 inhibitor, in combination with SpyADI.